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Background:Nitric oxide (NO), a potent vasodilator produced by endothelial cells, is reduced in patients with peripheral
arterial disease (PAD), but the mechanism has not been fully elucidated. Because NO is rapidly inactivated by superoxide
anion, we speculated that enhanced oxidative stress could lower NO generation. The aim of our study was to investigate
if an imbalance between oxidative stress andNO does exist in patients with PAD and if an increase of NO formation could
be achieved by an antioxidant treatment.
Methods: In a first study, serum levels of nitrite and nitrate (NOx), markers of NO generation, and 8-hydroxy-2-
deoxyguanosine (8-OHdG), a marker of oxidative stress and maximal walking distance (MWD), were measured in 40
PAD patients and 40 controls. In a second study, 10 PAD patients were randomly allocated in a crossover design to
intravenous propionyl-L-carnitine (6 g/day) or placebo for 7 days, with a washout of 30 days between the two phases of
the trial. Serum levels of NOx and 8-OHdG were measured before and after the study.
Results:Compared with controls, serum levels of 8-OHdG (mean SD) were significantly increased in PAD patients (4.4
 3.1 ng/mL vs 2.4 1.2 ng/mL; P< .001), and serum levels of NOx were significantly decreased (11.6 6 M vs 17
 6.1 M; P < .001). Levels of 8-OHdG and NOx were inversely correlated (r  0.879; P < .001). Serum levels
8-OHdG were inversely correlated with MWD (r0.48, P .002). The interventional trial showed no changes in the
patients given placebo. Patients treated with propionyl-L-carnitine showed a significant increase of MWD from 101 31
meters to 129  35 meters (P  .007) and in NOx from 14.5  4.5 M to 17.1  3.8 M (P  .007). A significant
decrease of 8-OHdG from 3.6  1.1 ng/mL to 2.6  1 ng/mL was also found (P  .005.)
Conclusions: This study suggests that in PAD patients, the reduction of NO generation could be dependent upon
enhanced oxidative stress. ( J Vasc Surg 2006;44:525-30.)Peripheral arterial disease (PAD) is caused by athero-
sclerosis of the leg arteries and is usually complicated by
vascular accidents occurring not only in peripheral circula-
tion but also in the cerebral and coronary trees.1 Approxi-
mately one third of patients with PAD have claudication,
that usually deteriorates slowly. Claudication worsens in
25% of patients and about 5% undergo amputation 5
years.2
Nitric oxide (NO) is synthesized from L-arginine and is
constitutively released by endothelial cells whereby it serves
to regulate vascular tone and inhibit platelet function.3 NO
is a potent antiatherosclerotic molecule, as indicated by
experimental study showing that L-arginine supplementa-
tion reduces atherosclerotic progression.4 NO generation
is reduced in patients with PAD, suggesting that it may
be implicated in the atherosclerotic progression,5 but the
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been fully elucidated. In particular, it has not been clarified
if the reduced generation of NO could be dependent on
enhanced oxidative stress that may reduce NO generation
via its accelerated degradation or inhibition of NO syn-
thase.6
Enhanced serum levels of isoprostanes and autoanti-
bodies against oxidized low-density-lipoprotein have been
detected in patients with PAD,7,8 suggesting that PAD
patients have high oxidative stress. However, to our knowl-
edge, whether a relationship between NO generation and
oxidative stress exists has never been explored in this clinical
setting. Therefore, the first aim of the study was to investi-
gate whether an imbalance between oxidative stress and
NO does exist in patients with PAD. The second aim of the
study was to analyze whether an increase of NO formation
could be achieved by an antioxidant treatment. To this
purpose an interventional trial was done with propionyl-
L-carnitine (PLC), a molecule that has been shown to reduce
cellular superoxide anion (O2
) production through inhi-
bition of arachidonic acid-dependent nicotinamide adenine
dinucleotide phosphate hydrogen (NADPH) oxidase acti-
vation.9
MATERIALS AND METHODS
The study was in two parts. First, we performed a
cross-sectional study comparing oxidative stress and NO
generation in a population of PAD patients, with healthy
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interventional trial in PAD patients to assess if PLC infusion
was able to reduce oxidative stress and in turn enhance NO
generation.
Cross-sectional study. The study included 40 con-
secutive patients, aged 40 to 80 years, who were affected
with PAD at Leriche Fontaine stage IIb and had symptoms
of intermittent claudication for at least 6 months. Each
patient visited as an outpatient in the ambulatory clinic of
our division. Forty subjects without clinically relevant ath-
erosclerotic disease were the controls.
PAD was defined according to the following criteria:
(1) claudication defined as leg pain on walking, disappear-
ing within 10minutes on standing, of presumed atheroscle-
rotic origin and (2) an ankle-brachial index (ABI), that was
assessed by Doppler ultrasonography as an ankle-arm sys-
tolic blood pressure ratio 0.80 on the worst leg at rest.
All patients underwent a full medical history, physical
examination, 12-lead electrocardiogram, laboratory tests,
measurement of ABI, and a screening treadmill test where-
upon the maximal walking distance (MWD) was recorded.
Patients had to be in a stable condition, without abrupt
changes of walking distance and ABI in the month before
the study. They were excluded if they had liver insuffi-
ciency, serious renal disorders (serum creatinine2.8 mg/
dL), and myocardial infarction, coronary revascularization,
peripheral vascular surgery or percutaneous intervention
procedure, unstable angina, acute cerebrovascular disease,
or deep venous thrombosis within 6months before hospital
admission. All participants provided written informed con-
sent.
Interventional study with PLC. Ten of the 40 pa-
tients were randomly allocated to a 12-hour intravenous
infusion of placebo or PLC (6 g/day for 7 days) in a
double-blind crossover design. There was a 1-month wash-
out between the two phases of the study. During the study
period, all patients were given a similar diet and checked for
blood pressure, glycemia, and pulse rate. Also, all patients
were nonsmokers and did not train during the entire period
of observation. All patients were hospitalized during each
period of the study. ABI and treadmill were measured at
baseline and 12 hours after the last infusion of placebo or
PLC. At baseline and 12 hours after the last infusion, a blood
sample was taken to measure serum NO and 8-OHdG. All
the analyses were performed blind. The protocol was ap-
proved by the regional committee for research ethics. All
participants provided written informed consent.
Treadmill test. Treadmill test was performed using a
treadmill speed of 3.5 km/h at 12% grade until maximal
claudication pain.
ABI measurement. The ABI was calculated with the
patient placed in the supine position, measuring the higher
systolic pressure of the anterior or posterior tibial artery in
each limb, and dividing this pressure with the highest
brachial systolic pressure.10 We performed toe pressure
determinations in patients with diabetes. The ABImeasure-
ment was obtained 5 minutes before the exercise.Blood sampling protocol. Subjects underwent rou-
tine biochemical evaluation, including fasting, and serum
levels of total and high-density-lipoprotein cholesterol,
triglycerides, glucose, and insulin. After overnight fasting
and supine rest for at least 10 minutes, blood was with-
drawn from an antecubital vein.
Serum levels of nitrite/nitrate and 8-hydroxy-2-
deoxyguanosine. Blood samples were immediately cen-
trifuged at 3000 rpm for 15 minutes at 4°C, and the
supernatant was collected and stored at 80°C until
measurement. NO serum levels were evaluated through the
measurement of metabolic end products (Calbiochem ni-
trite nitrate assay, CN Biosciences, San Diego, Calif), ni-
trite and nitrate (NOx) using enzymatic catalysis coupled
with Griess reaction as reported by Verdon.11 Intra-assay
and inter-assay coefficients of variation were 2.2% and 4.0%,
respectively.
Serum levels of 8-OHdG were analyzed by using a
competitive enzyme-linked immunosorbent assay (Bioxytech
8-OHdG-EIA, OXIS Health Products, Portland, Ore).
Intra-assay and inter-assay coefficients of variation were 2.1%
and 4.5%, respectively. Day-to-day variation of NO and
8-OHdG was 3% and 3.2%, respectively.
Statistical analysis. Assuming that PLC treatment
would reduce serum levels of 8-OHdG by 30%, we postu-
lated that the study sample size should consist of at least 10
patients for each group (  0.05, 1–  0.80). Categoric
variables are reported as counts (percentage) and continu-
ous variables as means  SD, unless otherwise indicated.
Independence of categoric variables was tested by  2 test.
Comparisons between groups were performed by Student’s
t test and were replicated as appropriate with nonparamet-
ric tests (Wilcoxon and Kolmogorov-Smirnov z test in case
of nonhomogeneous variances as verified by Levene’s test).
Analysis of variance with a Bonferroni test for multiple
comparisons was applied in vitro experiments. The correla-
tion analysis was done with Pearson’s test. Multiple linear
regression analysis was performed by using stepwise selec-
tion method. A value of P .05 was considered statistically
significant. All analyses were done with SPSS 13.0 software
(SPSS Inc, Chicago, Ill).
RESULTS
Cross-sectional study. Clinical characteristics of pa-
tients with PAD (Table I) included hypertension in
87.5%, dyslipidemia in 52.5%, diabetes in 32.5%, 60% were
ex smokers, and 5% had a clinical history of myocardial
infarction (MI). Concomitant treatments included antico-
agulants (10%), antiplatelets agents (95%), angiotensin-
converting enzyme inhibitors (55%), calcium antagonists
(45%), doxazosin (10%), diuretics (55%), oral antidiabetic
drugs (25%), insulin (7.5%), and statins (45%).
Compared with controls, patients with PAD had en-
hanced oxidative stress as documented by elevated serum
levels of 8-OHdG (4.4 3.1 ng/mL vs 2.4 1.2 ng/mL;
P  .001) (Fig1, A). NOx generation was significantly
reduced in PAD patients compared with controls (11.6 
6 	M vs 17  6.1 	M; P  .001) (Fig1, B). A significant
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NOx (r  0.879; P  .001) (Fig 2). To further analyze
the relationship between these values, we calculated the
NOx/8-OHdG ratio for each patient and found a lower
ratio in PAD patients compared with controls (5.9 5.1 vs
16.7  14, P  .001).
In patients with PAD, MWD was 79  32 meters.
MWD was correlated directly with NOx (r  0.36, P 
.02) and inversely with 8-OHdG (r  0.48, P  .002).
To establish the independent predictors of 8-OHdG in
PADpatients, we performed amultivariate linear regression
(adjusted for age, ABI, systolic and diastolic blood pres-
sure, smoking history, diabetes and dyslipidemia) showing
that NOx (B, 0.410; ES, 0.039; standardized coefficient
, 0.810; P  .001) and MWD (B, 0.017; ES, 0.007;
standardized coefficient :0.194; P .017) were signif-
icantly associated. The same statistical analysis (adjusted for
age, ABI, systolic and diastolic blood pressure, smoking
history, diabetes and dyslipidemia) performed to establish
the independent predictors of NOx showed that only
8-OHdG (B, 1.736; ES, 0.152; standardized coefficient
: 0.879; P  .001) was significantly associated.
Interventional trial. Clinical characteristics of the pa-
tients who participate in the interventional study were
similar to the clinical characteristics of the entire PAD popu-
lation (Table II). In patients given placebo, no changes in
MWD (100 29 meters to 103 33 meters; P .05), or
in NOx and 8-OHdG serum levels were observed (Fig 3).
Conversely in patients given PLC, we observed a significant
Table I. Clinical characteristics of patients with PAD and
healthy subjects
Variables
Healthy subjects PAD
P(n  40) (%) (n  40) (%)
Mean age (yr) 64.2  11.2 64.9  7.4 NS
Males/females 30/10 31/9 NS
Hypertension 37.5 87.5 .001
Diabetes mellitus 0 32.5 .001
History of MI 0 5 NS
Dyslipidemia 40 52.5 NS
Ex smokers 30 60 .013
Medication
ACE-inhibitors 25 55 .012
Diuretics 27.5 55 .023
Calcium antagonists 15 45 .007
Doxazosin 5 10 NS
Oral antidiabetic
drugs 0 25 .002
Insulin 0 7.5 NS
Antiplatelets agents 0 95 .001
Anticoagulants 0 10 NS
Statins 7.5 45 .001
NOx (	mol/L) 17  6.1 11.6  6 .001
8-OHdG (ng/mL) 2.4  1.2 4.4  3.1 .001
ABI 1.2  0.11 0.54  0.14 .001
PAD, Peripheral arterial disease;MI,myocardial infarction; ACE, angiotensin-
converting enzyme; NS, not significative; NOx, nitrite and nitrate; 8-OHdG,
8-hydroxy-2-deoxyguanosine; ABI, ankle-brachial index.
Data are expressed percentages, a ratio, or as mean  SD.increase in MWD (101  31 meters to 129  35 meters;P  .007) and in serum levels of NOx (14.5  4.5 	M to
17.1  3.8 	M; P  .007) (Fig 3). A decrease of 8-OHdG
(3.6  1.1 ng/mL to 2.6  1 ng/mL; P  .005) was also
found (Fig 3). Before (r 0.96; P  .001) and after (r 
0.91, P  .001) PLC treatment, NOx and 8-OHdG
serum levels were inversely correlated. Furthermore, we
found an increase in the NOx/8-OHdG ratio for each
patient from 5.4  3.7 to 9.1  4.6 (P  .001).
DISCUSSION
Low generation of NO in patients with PAD may have
a deleterious effect in the progression of this vascular pa-
thology because NO is potent inhibitor of platelet function
and possesses antiatherosclerotic property that could limit
the progression of atherosclerotic plaque. In accordance
with previous findings,5 patients with PAD had low levels
of systemic NO that could be dependent upon its reduced
synthesis or rapid catabolism. In particular, Boger et al5
demonstrated that patients with PAD have enhanced levels
of asymmetric dimethyl-L-arginine, an endogenous inhib-
itor of NO synthase, suggesting that in this setting, lowNO
generation could be due to reduced NO synthesis.
In the present study, we sought to investigate an alter-
native mechanism that may account for low NO genera-
tion. In particular, we analyzed the existence of a relation-
ship between NO generation and oxidative stress that is
known to inhibit NO generation. Our findings are in accor-
dance with previous studies7,8,12 documenting enhanced
oxidative stress in patients with PAD. In particular, Berg-
mark et al13 demonstrated increased circulating levels of
autoantibodies against oxidized low-density lipoprotein in
62 PAD patients with no difference between patients with
moderate or severe peripheral atherosclerosis. Mueller et
al7 found elevated serum levels of isoprostanes that were
independent predictors of PAD. In 85 PAD patients, Lan-
glois et al12 detected low serum levels of vitamin C, a
known antioxidant, that were independent of smoking
habit and hypertension.
The novel finding of the present study is the demon-
stration of an inverse relationship between oxidative stress
and NO, suggesting that in PAD oxidative stress may
determine low NO generation. To explore this issue we
performed an in vivo study with PLC, a molecule that
exerts an antioxidant activity via reduction of arachidonic
acid-dependent NADPH oxidase activation.9
The study was a double blind placebo-controlled trial
in PAD patients to assess if PLC administration was able to
interfere with serum levels of 8-OHdG andNOgeneration.
As PLC bioavailability is low by oral administration,14-16
the trial was performed by intravenous PLC infusion. After
PLC administration, we observed a parallel decrease of
oxidative stress and increase of NO generation. The fact
that an antioxidant treatment was able to enhance NOx
serum levels suggests that in PAD patients, oxidative stress
is implicated in lowering NO generation.
This hypothesis is consistent with the study by Ruano
et al17 showing that in hypercholesterolemic patients, oxi-
dative stress and NOx were inversely correlated but does
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anisms may be implicated in the reduction of NOx by PLC.
First, the reduction of oxidative stress could result in en-
hancing NO bioavailability but against this possibility is the
fact that NOx may also stem from NO interaction with
O2
. This hypothesis, however, cannot be fully excluded
because NOx can also stem from amechanism independent
of O2
.18,19
An alternative and more intriguing hypothesis is that
oxidative stress reduces NO generation via inhibition of
Fig 1. A, Serum levels of 8-hydroxy-2-deoxyguanosine
and in control subjects. B, Nitrite and nitrate (NOx) ser
are expressed as mean  SE.
Fig 2. Correlation between nitrite and nitrate (NOx) and 8-hy-
droxy-2-deoxyguanosine (8-OHdG) in patients with peripheral
arterial disease (PAD).NO synthase6; therefore, the reduction of NOx serumlevels should be interpreted as a consequence of lowered
NO synthesis more than accelerated NO degradation. Fur-
ther study is therefore necessary to elucidate the intrinsic
mechanism through which oxidative stress reduces NO
generation in PAD patients.
CONCLUSION
Our findings may have potential clinical implications.
Previous studies underscored the relevance of endothelium-
derivedmediators for vasodilatation in the microcirculation
HdG) in patients with peripheral arterial disease (PAD)
vels in patients with PAD and in control subjects. Data
Table II. Clinical characteristics of patients undergoing
interventional trial with propionyl-L-carnitine
N 10
Mean age (year) 62.5  6.6
Males/Females 8/2
Hypertension 100
Diabetes mellitus 30
Dyslipidemia 50
History of MI 0
Ex smokers 70
Medication
ACE inhibitors 60
Diuretics 40
Calcium antagonists 30
Doxazosin 20
Oral antidiabetic drugs 30
Insulin 0
Anti-platelets agents 100
Anticoagulants 0
Statins 50
MI, Myocardial infarction; ACE, angiotensin-converting enzyme.
Data are expressed as percentages, a ratio, or as mean  SD. (8-O
um leof skeletal muscle. Maxwell et al20 demonstrated, in partic-
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walking performance through limiting oxygen delivery to
skeletal muscle. Also, an interventional trial with L-arginine
favored the role of NO in exercise performance.21 Thus,
administration of L-arginine to patients with claudication
resulted in a significant increase of MWD.21,22
Our data suggest that the use of an antioxidant could
represent an alternative approach to cure PAD patients,
because the reduction of oxidative stress would result in
enhancing NO bioavailability and, eventually, walking per-
formance. This hypothesis could be supported by the in-
verse correlation between oxidative stress andMWDand by
the increase of MWD after PLC treatment. However, the
small sample size of interventional trial precludes definite
conclusions and suggests that this hypothesis be tested in a
larger population.
In conclusion, this study shows that in patients with
PAD low NO generation may result from enhanced oxida-
tive stress and suggests that antioxidant treatment is useful
to counteract it.
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